BAP-1 likewise demonstrated exceptional glioma selectivity: thirty minutes post-injection, tumor fluorescence exceeded background by more than 2400-fold in PFA-fixed 15 μm slices and ~85-fold in live 300 μm slices (Figure 5 and Figure 6). This evidence concerns the gene BAP1 and central nervous system cancer.